# 16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer

Source: https://onco.cc/trials/nct07779694/  
OnCo record `nct07779694` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of serplulimab in colorectal cancer, run by Zhejiang University, not yet recruiting.

## Summary

16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer is a phase 2, interventional study registered as NCT07779694 by Zhejiang University, with a registry enrolment figure of 51 participants, started 2026-10-01 and due to reach its primary completion in 2028-12-31. Interventions recorded: 16-Hour Fasting; Serplulimab + chemotherapy. Conditions listed: pMMR/MSS; Locally Advanced Rectal Carcinoma; Fasting, Intermittent. Primary outcome: Pathological complete response rates. Colorectal eligibility wording from the registry: "Histological or cytological documentation of adenocarcinoma of the rectum". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07779694
- Phase: 2
- Setting: Neoadjuvant 16-Hour Fasting Combined With Serplulimab and CAPEOX for pMMR/MSS Locally Advanced Mid-to-Low Rectal Cancer: A Prospective, Single-Arm, Phase II Trial.
- Sponsor: Zhejiang University
- Enrolled: 51

## Sources

- ClinicalTrials.gov NCT07779694: https://clinicaltrials.gov/study/NCT07779694

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Serplulimab](https://onco.cc/drugs/serplulimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07779694.json